
    
      To assess the effect of Aranesp on the hemoglobin of CRI subjectswho are recombinant human
      erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy and to assess the association
      between subject self-reported health-related quality of life (HRQoL) as it relates to Hgb
      concentration and glomerular filtration rate (GFR) in subjects who were rHuEPO-naïve prior to
      study enrollment. To characterize the health-related resource utilization of subjects with
      CRI. To characterize the subject satisfaction with Aranesp™ compared to previous rHuEPO
      therapy. To characterize iron treatment in subjects with CRI. To assess the safety profile of
      Aranesp™ therapy in subjects with CRI.
    
  